EPS for Abbott Laboratories (ABT) Expected At $0.71 as of July, 19

June 29, 2018 - By Gregory Tomko

Abbott Laboratories (NYSE:ABT) Corporate Logo
During Q1 2018 the big money sentiment decreased to 0.83. That’s change of 0.08, from 2017Q4’s 0.91. 44 investors sold all, 606 reduced holdings as Abbott Laboratories ratio fall. 411 grew stakes while 126 funds bought stakes. Funds hold 1.22 billion shares thus 0.54% more from 2017Q4’s 1.22 billion shares.
Eagle Asset Mngmt has 0.13% invested in Abbott Laboratories (NYSE:ABT). Financial Engines Advsrs Ltd Co reported 99,335 shs stake. Dearborn Prns Lc reported 60,508 shs. Prelude Mgmt Limited stated it has 21,130 shs. Optimum Investment Advsr reported 13,712 shs. Transamerica Financial Advsr Inc invested in 17 shs or 0% of the stock. Moreover, Country Tru Bancorp has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 3,656 shs. Mai Cap Mgmt holds 0.88% or 257,455 shs. Michigan-based World Asset Mgmt Inc has invested 0.3% in Abbott Laboratories (NYSE:ABT). Bancshares Of Stockton has 0.58% invested in Abbott Laboratories (NYSE:ABT). Endurance Wealth Mgmt reported 705 shs. Polar Capital Llp has invested 0.89% in Abbott Laboratories (NYSE:ABT). Hap Trading Ltd Liability Com, a New York-based fund reported 23,116 shs. Shell Asset Mgmt owns 379,091 shs or 0.45% of their US capital. Colony Gp Ltd Liability Corporation holds 128,467 shs or 0.42% of its capital.

Abbott Laboratories registered $22.32 million net activity with 1 insider buy and 20 sales since January 30, 2018. Watkin Jared had sold 996 shs worth $58,635 on Wednesday, February 28. On Wednesday, February 28 BIRD ROGER had sold 1,645 shs worth $96,728. 27,733 Abbott Laboratories (NYSE:ABT) shs with value of $1.73 million were sold by Blaser Brian J. Salvadori Daniel Gesua Sive had sold 905 shs worth $53,369 on Wednesday, February 28. 849 shs valued at $50,397 were sold by Contreras Jaime on Monday, April 23. Ford Robert B sold $2.69M worth of Abbott Laboratories (NYSE:ABT) on Tuesday, January 30.

On July, 19. Investors wait Abbott Laboratories (NYSE:ABT) to announce its quarterly earnings, Zacks reports. Analysts predict $0.71 earnings per share, which is $0.09 up or 14.52 % from 2017’s $0.62 earnings per share. ABT’s profit could be $1.24 billion if the current earnings per share of $0.71 is accurate. 20.34 % EPS growth is what analysts predict. $0.59 earnings per share was revealed for previous quarter. ABT is hitting $61.8 during the last trading session, after increased 0.87%.Abbott Laboratories has volume of 1.20 million shares. Since June 29, 2017 ABT has risen 41.91% and is uptrending. ABT outperformed by 29.34% the S&P 500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 15 analysts cover Abbott Laboratories (NYSE:ABT). “Buy” rating has 13, “Sell” are 0, while 2 are “Hold”. (NYSE:ABT) has 87% bullish analysts. 20 are the (NYSE:ABT)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, January 24 Jefferies maintained Abbott Laboratories (NYSE:ABT) with “Buy” rating. On Thursday, January 25 the firm has “Overweight” rating given by JP Morgan. On Wednesday, January 24 the stock has “Buy” rating by BMO Capital Markets. The company rating was maintained by Wells Fargo on Thursday, January 25. On Thursday, January 25 the stock of Abbott Laboratories (NYSE:ABT) has “Overweight” rating given by Morgan Stanley. On Thursday, January 25 the rating was maintained by Barclays Capital with “Overweight”. On Tuesday, April 24 the rating was maintained by Citigroup with “Neutral”. On Tuesday, January 30 the company was maintained by Citigroup. On Wednesday, January 24 RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating. RBC Capital Markets has “Buy” rating and $67.0 target. On Tuesday, January 2 the rating was upgraded by Morgan Stanley to “Overweight”.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is valued at $108.35 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.231.46 is the P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More recent Abbott Laboratories (NYSE:ABT) news were brought out by Streetinsider.com, Seekingalpha.com and Streetinsider.com. The first one has “Abbott (ABT) Says New Late-Breaking Data at ADA Underscore Significant Benefits of its FreeStyle Libre System” as a title and was brought out on June 25, 2018. The next is “Medical device makers ISRG, BSX, ABT started with bullish view at Bernstein” on June 27, 2018. And last was brought out on June 28, 2018, called “Bernstein Starts Abbott Labs (ABT) at Outperform”.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.